Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis
Open Access
- 25 August 2025
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (9) , 1261
Abstract
Type 2 diabetes mellitus (T2DM) is frequently complicated by atherosclerosis (AS), with substantial overlap in their underlying pathophysiological mechanisms, posing serious threats to patient health. Tirzepatide, a novel dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has demonstrated remarkable efficacy in glycemic control, weight reduction, and cardiometabolic improvement, making it a promising candidate for managing T2DM comorbid with AS. However, substantial interindividual variability in treatment response suggests a role for genetic determinants. This review systematically summarises current evidence on pharmacogenomic variants influencing the efficacy and toxicity of tirzepatide, explores the interplay between drug response genes and genetic susceptibilities to T2DM and AS, and highlights the potential of pharmacogenomics in guiding precision subtyping and individualised therapy. Finally, we highlight key challenges and future directions in the clinical translation of tirzepatide pharmacogenomics, aiming to inform personalized, genomics-guided therapy for cardiometabolic disease.Keywords
Funding Information
- Natural Science Foundation of China (82170485, 2023JJ30426)
- Natural Science Foundation of Hunan Province (82170485, 2023JJ30426)
This publication has 114 references indexed in Scilit:
- A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesityObesity, 2025
- Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and futureMedicinal Research Reviews, 2024
- Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 DiabetesJAMA Network Open, 2024
- The expanding incretin universe: from basic biology to clinical translationDiabetologia, 2023
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 DiabetesJAMA, 2022
- Racial and Ethnic Differences in Drug Disposition and Response: Review of New Molecular Entities Approved Between 2014 and 2019The Journal of Clinical Pharmacology, 2021
- GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled studyDiabetologia, 2019
- Apolipoprotein E: from cardiovascular disease to neurodegenerative disordersJournal of Molecular Medicine, 2016
- The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy menDiabetologia, 2009
- Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphismsDiabetologia, 2007